RankAlpha logo
Back to Rankings

COR

CencoraF
NYSE / Health Care Equipment & Services
Last Price
At close
2026-06-02
View Chart
Current thesis
The strongest post-print argument is that the market can look past a modest consensus miss because the company raised FY2026 adjusted EPS guidance to $17.65-$17.90, cited strong U.S. Healthcare Solutions operating-income growth, and showed OneOncology already helping mix and gross profit [#8-K-2026-05-06].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.6.
What can break
Acquisition financing materially increased debt: total debt rose to about $12.4 billion at March 31, 2026 from about $7.7 billion at September 30, 2025, raising interest-cost sensitivity after OneOncology [#10-Q-2026-05-06].
Momentum
7
Value
66
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $275.00 · Bull $300.00 · Bear $235.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $412.62
Why
Momentum7 · Δ7d -0.2
Value66 · Δ7d +0.6
Sentiment46 · Δ7d +7.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
7
34% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-4.6
Value
66
32% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
-0.0
Sentiment
46
33% active weight
Current posture
7d trendImproving
Δ7d
+7.3
Δ21d
+6.0
Why this grade

Composite grade F. Momentum 7.0 / Value 66.3 / Sentiment 46.2

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$51.5B
Beta
0.68
Shares Out
387.93M
P/E (TTM)
42.9
P/S (TTM)
0.21
P/FCF (TTM)
23.88
Rev YoY
+5.9%
EPS YoY
-10357.4%
Gross Margin
+3.5%
Op Margin
+0.8%
Net Debt
$3.3B
Current Ratio
0.90
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology